We performed a multicenter , randomized , open-label , phase 3 trial of the efficacy and safety of adjuvant immunotherapy with activated CIK cells ( created by incubation of patients ' peripheral blood mononuclear cells with interleukin 2 and an antibody against CD3 ) .